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Abstract
BACKGROUND: Conventional frequency quantitative ultrasound in conjunction with textural analysis tech-
niques was investigated to monitor noninvasively the effects of cancer therapies in an in vivo preclinical model.
METHODS: Conventional low-frequency (∼7 MHz) and high-frequency (∼20 MHz) ultrasound was used with
spectral analysis, coupled with textural analysis on spectral parametric maps, obtained from xenograft tumor–
bearing animals (n = 20) treated with chemotherapy to extract noninvasive biomarkers of treatment response.
RESULTS: Results indicated statistically significant differences in quantitative ultrasound-based biomarkers in
both low- and high-frequency ranges between untreated and treated tumors 12 to 24 hours after treatment.
Results of regression analysis indicated a high level of correlation between quantitative ultrasound-based bio-
markers and tumor cell death estimates from histologic analysis. Applying textural characterization to the
spectral parametric maps resulted in an even stronger correlation (r2 = 0.97). CONCLUSION: The results
obtained in this research demonstrate that quantitative ultrasound at a clinically relevant frequency can monitor
tissue changes in vivo in response to cancer treatment administration. Using higher order textural information
extracted from quantitative ultrasound spectral parametric maps provides more information at a high sensitivity
related to tumor cell death.
Translational Oncology (2013) 6, 234–243
Introduction
Cancer patients respond differently to identical treatments. As such,
a predefined therapy is not often effective for all patients. This makes
the early detection of patients refractory to a specific therapy critical,
since this could facilitate a switch to an early salvage therapy or a
change to a more effective primary treatment [1]. For example, locally
advance breast cancer patients can considerably benefit from an early
evaluation of their ultimate response to the neoadjuvant chemotherapy,
as an important component of their therapy, since a complete patho-
logic response to neoadjuvant chemotherapy has been demonstrated to
have a strong correlation with patient survival [2–4]. However, this
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prognostic factor is frequently assessed at the time of surgery, and at this
time, the window for modifying neoadjuvant treatment is already
passed. Standard anatomic-based imaging can detect macroscopic
changes in tumor size as a measure of treatment response. However,
such changes often take many weeks to months to develop, and in some
cases, abnormal tissue diminishment is not detectable even with a pos-
itive treatment response [5]. Functional imaging, including magnetic
resonance imaging, diffuse optical imaging, and positron emission
tomography, has been demonstrated as a method capable of detecting
tumor responses after starting therapy [5–7]. Such methods that mea-
sure tumor physiology noninvasively could be used to facilitate changes
in treatment to improve the patient’s prognosis. In this context, quan-
titative ultrasound techniques have been recently demonstrated to be
able to quantify changes in tissue microstructures that can be linked
to effects of cancer therapies including apoptotic cell death. This has
been demonstrated through several in vitro, in situ, and in vivo studies
using high-frequency quantitative ultrasound techniques [8–15]. Ultra-
sound imaging is a high-resolution portable imaging modality with low
cost and rapid imaging speed. In addition, unlike other modalities pro-
posed for therapy response monitoring, it does not require injection of
any contrast agents. This is principally due to the fact that alterations in
the physical properties of dying cancer cells are the main source of the
changes in image contrast and spectral features associated with tumor
response [8].
Quantitative ultrasound techniques have been used in several tissue
characterization applications where they have demonstrated capabili-
ties for differentiating between tissues with different intrinsic micro-
structures. Such applications include the diagnosis of cardiac and liver
abnormalities, prostate cancer, and the differentiation of benign from
malignant diseases [16–18]. Specifically, with respect to breast cancer
applications, Oelze et al. used quantitative ultrasound to differentiate
fibroadenomas from mammary carcinomas and sarcomas [19].
Initial investigations for detecting apoptosis using quantitative ultra-
sound were performed using high-frequency (20–50 MHz) ultrasound
with acute myeloid leukemia cell samples in vitro exposed to the chemo-
therapeutic agent cisplatin. Large increases obtained in the ultrasound
backscatter amplitude demonstrated an increased tissue echogenicity
24 hours after drug exposure that were associated with cell death [8,9].
In subsequent studies, cellular nuclear structure was further linked to
ultrasound backscatter properties in an examination of different cell
types and their isolated nuclei in which speed of sound, attenuation
coefficient, and integrated backscatter coefficient were measured [15].
The findings suggested that integrated backscatter coefficient values,
but not attenuation or speed of sound, were correlated with the size of
the nuclei. Further experiments conducted onmixtures of apoptotic cells
and viable cells using high-frequency quantitative ultrasound indicated
further increases in backscattered signal intensity compared to pure
populations of apoptotic cells, indicating a role for effects of scatterer
positions and their potential randomization in contributing to increases
associated with cell death in vivo [11]. High-frequency quantitative ultra-
sound techniques have also been applied successfully in the detection of
effects of photodynamic therapy and radiation therapy in other studies
[12–14]. Those studies demonstrated that high-frequency ultrasound
is sensitive to structural changes associated with cell death with con-
siderable increases in ultrasound-based measures, such as backscattered
signal intensity, which were accompanied by changes in spectral slope
and 0-MHz intercept biomarkers (defined later).
One major limitation for the clinical application of high-frequency
ultrasound is the limited depth of its penetration that constrains its
use to superficial tissues. Conventional frequency (1–20 MHz) ultra-
sound, which is broadly used in medicine, benefits from a deeper
tissue penetration but has a lower resolution (80 μm–1.5 mm). As
such, conventional frequency ultrasound may potentially be able to
evaluate patient responses to treatment for a variety of deeper sited
cancers [20] such as liver [21–23], kidney [24–26], and breast [27–
29] malignancies. The application of conventional frequencies to
monitor morphologic alterations associated with cell death could
accordingly permit evaluation of response to the cancer therapies and
facilitate switching from ineffective treatments to more efficacious ones.
In this study, we investigate the potential of clinically relevant con-
ventional frequency quantitative ultrasound to monitor noninvasively
the effects of cancer therapies in an in vivo preclinical model. Assess-
ments of xenograft tumor responses to cancer treatments were carried
out using low-frequency (∼7 MHz) ultrasound to demonstrate the
feasibility of using conventional frequency quantitative ultrasound to
detect and monitor cell death. Human breast cancer (MDA)–bearing
mice were treated with intravenous paclitaxel-doxorubicin, and high-
and low-frequency ultrasound data were acquired at different times
after exposure. Ultrasound data analysis used linear regression analysis
of the power spectrum, statistical analysis of the signal envelope, and
novel texture analysis on spectral parametric maps as early biomarkers
of treatment response to assess response heterogeneity. Results demon-
strate the capacity of conventional frequency ultrasound integrated with
textural analysis techniques in monitoring apoptotic tumor cell death
resulting from cancer therapy administration. Statistically significant
differences were revealed after 12 and 24 hours for both spectral and
textural changes in midband fit (MBF) and 0-MHz intercept, respec-
tively, as quantitative ultrasound-based biomarkers of treatment re-
sponse. Regression analysis also revealed a strong correlation between
changes in these ultrasonic biomarkers and the percentage of tumor
cell death obtained from histologic analysis (r2 = 0.97 for hybrid tex-
tural biomarkers). This research, thus, extends the applicability of
quantitative ultrasound methods to clinical ranges of ultrasound for
the detection of cell death in vivo.
Materials and Methods
Experimental Design and Data Collection
This study was conducted with research ethics approval from the
Animal Care Committee of Sunnybrook Research Institute (Protocol
No. 11-440). All animal handling was in accordance with the recom-
mendations of the Canadian Council on Animal Care, requirements
under the Animals for Research Act, RSO 1980, and institutional
animal care committee policies and guidelines. Human breast cancer
cells [MDA-MB-231; American Type Culture Collection (ATCC),
Manassas, VA] were injected (1 × 106 cells) and permitted to grow to
a size of 7- to 9-mm xenograft tumors in the hind leg of severe com-
bined immunodeficiency disease (SCID) mice. Mice were anesthetized
before imaging using 100 mg/kg ketamine, 5 mg/kg xylazine, and
1 mg/kg acepromazine (CDMV, St Hyacinthe, Quebec). Anesthetized
animals were treatedwith paclitaxel-doxorubicin (150mg/m2, 50mg/m2,
respectively) through intravenous tail vein injection. Experimentation
used 20 animals (five groups of n = 4), one of which remained untreated
as a control group. Each of the groups was assessed at a different time
after chemotherapy exposure, i.e., 0, 4, 12, 24, and 48 hours, respec-
tively, to determine the effect of treatment time on tumor response.
Each mouse was imaged twice, i.e., before and after treatment. All
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animals were killed following experiment, and tumors were excised for
histologic examination.
Ultrasound radiofrequency (RF) data were collected using both
conventional low- and high-frequency ultrasound. For low-frequency
ultrasound, a Sonix RP System (Ultrasonix, Vancouver, British
Columbia) was used with an L14-5/38 transducer with a transmit
frequency of 10 MHz resulting in a bandwidth with a center fre-
quency of ∼7 MHz, focused at 1.5-cm depth, with data sampled
at 40 MHz. High-frequency data were collected using a Vevo 770
System (Visual Sonics, Toronto, Ontario) using a transducer (RMV-
710B) with a transmit frequency of 25 MHz resulting in a bandwidth
with a center frequency of ∼20 MHz, focused at 9-mm depth, with
data sampled at 420 MHz. Both systems were used to collect three-
dimensional data with scan plane separations of ∼0.5 mm in the
conventional frequency data and ∼0.1 mm in the high-frequency data.
Ultrasound RF Data Analysis
Ultrasound RF data analysis was performed using the normalized
power spectrum [8–10,12–14,17–19,30–32], and novel textural
analysis on spectral parametric maps [27,33], to extract quantitative
biomarkers of treatment response. Statistical analysis of the signal
envelope [11,34] was also performed as an adjunct study.
Statistical tests of significance based on changes in determined
parameters, compared to pretreatment data, were carried out using
one-way analyses of variance (ANOVAs, α = 0.05) over all treatment
groups, for both conventional frequency and high-frequency data.
Fisher’s least significant difference (LSD) post hoc tests were then
performed for each significant parameter to identify the treated groups
with significant difference compared to the untreated control group.
Normalized spectral parameters. Ultrasound data were analyzed
across 10 to 14 equally spaced scan planes with a size of 3.8 by
3.0 cm. Standardized regions of interest (ROIs), which were located
at the tumor center, were used for analysis. Power spectra were cal-
culated using a Fourier transform of the raw RF data for each scan
line through the ROI and subsequently averaged. Data were normal-
ized with a calibration pulse obtained from a flat quartz plate for high-
frequency data [30]. Conventional frequency data normalization used
the averaged power spectrum obtained from an agar-embedded glass-
bead phantom model [35]. This was used for conventional frequency
data, since it more accurately represented the frequency distribution
obtained in tissue power spectrum data than that obtained from a
quartz reflector at low frequencies. In addition, since conventional
frequency ultrasound is eventually intended for clinical applications,
phantom normalization can provide an approximate attenuation
correction with depth, particularly for cases in which tumors are
not superficial, e.g., in breast. Linear regression analysis was per-
formed on the averaged power spectrum within a center frequency–
based –6 dB window to generate a best-fit line. Parameters extracted
include the MBF, the spectral slope, and the corresponding 0-MHz
intercept [31,32,36,37].
Textural parameters. Spectral parametric maps were generated
through a sliding window analysis within the ROI on a pixel-by-pixel
basis, using a Hamming function. Maps were generated for MBF and
0-MHz intercept parameters as these parameters were relatively
strongly correlated to tumor response on ROI-based average analysis.
Texture analysis on parametric maps of MBF and 0-MHz intercept
was performed on the basis of a gray-level co-occurrence matrix
(GLCM), which represents the angular relationship between neigh-
boring pixels as well as the distance between them [27,33]. Sixteen
symmetric GLCMs were constructed considering each pixel’s neigh-
bors located at a distance of one to four pixels with angular values of
0° to 135° at 45° increments. Textural parameters (contrast, energy,
and homogeneity) were extracted from the corresponding GLCMs of
each spectral parametric map and were subsequently averaged [33].
Statistical parameters. Confirmatory statistical analysis of the signal
envelope, another method to quantify ultrasound signals, was per-
formed through measurements of the acquired signal’s envelope histo-
gram [38] by probability density function estimation [11]. Probability
density function estimation of the envelope histogram was carried out
by fitting a Rayleigh distribution that provided a suitable fit to both
low- and high-frequency data [34].
Histologic Analysis
Histologic analysis was performed on tumor samples fixed in
5% formalin for 24 to 48 hours. Fixed tumor sections were cut in
three representative planes with hematoxylin and eosin (H&E) stain-
ing carried out in addition to in situ end nick labeling (ISEL) immuno-
histochemistry for cell death. Microscopy was performed using a
Leica DC100 microscope with a ×20 objective and a Leica DC100
camera connected to a 2-GHz PC running Leica IM1000 software
(Leica GmbH, Wetzlar, Germany). Cell death areas were quantified
from immunohistochemistry-stained tumor sections using ImageJ
(National Institutes of Health, Bethesda, MD). At higher magnifica-
tions (×40), apoptotic cells were counted manually by identifying
typical apoptotic bodies. Cell death areas identified had more than
50% of cell death occurring within quantified regions.
Results
Ultrasound data indicated changes in quantitative parameters as
noninvasive ultrasound-based biomarkers that could be correlated
to the presence of cell death. Figure 1 illustrates representative ultra-
sound images and histologic data obtained for different times after
chemotherapy treatment. Ultrasound results demonstrated increases
in backscattered signal intensity and changes in spectral parameters
compared to pretreatment data (discussed further below). In general,
longer times after treatment typically resulted in larger areas of cell
death within the tumor and smaller cell and nucleus sizes, as presented.
Figure 2 presents representative parametric maps of the 0-MHz inter-
cept response biomarker overlaid on the corresponding ∼7-MHz ultra-
sound B-mode images for untreated control as well as for different
times after treatment. These maps demonstrate the use of a quantitative
ultrasound parameter to monitor the treatment response for each indi-
vidual tumor and can be used to discriminate differences in response
between groups of tumors. These maps also demonstrate hetero-
geneities in the parameters spatially and served as inputs into texture-
based analyses.
Specifically, mean increases in the MBF biomarker (MBFΔ) of 0.0 ±
0.1 dBr, 1.7 ± 0.2 dBr, 2.4 ± 0.2 dBr, 6.2 ± 0.3 dBr, and 7.2 ± 1.3 dBr
were observed for 0, 4, 12, 24, and 48 hours after treatment, respec-
tively. A similar trend was obtained for the 0-MHz interceptΔ bio-
marker. Results obtained for these spectral parameters have been
summarized in Figure 3. As this figure indicates, the data obtained
for conventional frequency ultrasound paralleled results observed for
high-frequency data for the same treatment groups, respectively.
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Spectral slope changes were less prominent and were not shown to be
statistically significant (Figure W1).
Results associated with textural parameters are presented in Fig-
ure 4 and consist of relative changes in contrast, energy, and homo-
geneity biomarkers. These were extracted from MBF and 0-MHz
intercept parametric maps following the treatment and compared
to pretreatment counterparts. Since the resolution of the parametric
maps is affected by the axial and lateral resolution in low- and high-
frequency ultrasound data that are different, averages of relative
changes in the textural parameters were determined to monitor the
treatment response. This permitted a direct comparison of the low-
and high-frequency data demonstrating similar trends. The results
presented in Figure 4 indicate considerable changes in the textural
properties of spectral parametric maps for chemotherapy-treated
animal-based tumors compared to the untreated control tumors.
Whereas the data obtained for conventional frequency ultrasound
paralleled results observed for high-frequency data, the high-frequency
data demonstrated a greater increase, on average, in the textural param-
eters extracted from 0-MHz intercept parametric maps. Changes in the
textural parameters of MBF parametric maps for high- and conven-
tional frequency data were similar. Results associated with the statistical
histogram-based biomarkers demonstrated similar trends, in general,
in comparison to those obtained from spectral and textural-based
monitoring (Figure W1).
Table 1 outlines the outcomes of tests of significance performed
for each response biomarker, using ANOVA test followed by LSD
Figure 1. Representative data obtained 0, 4, 12, 24, and 48 hours after treatment. (A) Representative∼7-MHz ultrasound B-mode images
of MDA tumors demonstrating increases in tissue echogenicity with treatment in contrast to untreated tumor. The scale bar represents
∼3 mm. (B) Representative normalized power spectra obtained from each tumor before treatment and afterward. (C) Low-magnification
light microscopy images of ISEL-stained tumors. The scale bar represents ∼1 mm. (D) Average cell and nucleus sizes measured for
different times after treatment using high-magnification images of H&E-stained tumor slices (left) and mean areas of apoptotic cell death
measured for different times after treatment using ISEL staining (right). Error bars represent ±1 SD. Stars represent statistically signif-
icant differences (P < .05) in comparison to the control.
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post hoc test for the significant biomarkers. According to the results
presented, average changes in the MBF biomarker, as well as in the
contrast of its corresponding parametric maps, showed statistically
significant differences compared to the untreated control group, after
12 hours of chemotherapy for both conventional and high-frequency
data. Statistically significant differences were revealed for the 0-MHz
intercept biomarker and its corresponding textural parameters after
12 to 24 hours of therapy for low- and high-frequency data.
Histologic analyses of breast cancer xenograft tumor responses to
treatment administration were carried out using light microscopy and
image analysis with H&E and ISEL staining to quantify macroscopic
regions of cell death tissue response (Figure 1). Staining for cell death
revealed 8 ± 2%, 20 ± 12%, 22 ± 10%, 61 ± 24%, and 42 ± 11%
mean areas (±SD) of apoptotic cell death in tumor samples 0, 4, 12,
24, and 48 hours after treatment, respectively. Tests of significance
indicated that there were statistically significant differences between
the amounts of histologic apoptotic cell death beginning 24 hours
after treatment compared to the untreated control animals (Table 1).
Linear regression analyses were performed to evaluate correlations
between changes in the conventional frequency ultrasound spectral
parameters, or the relative changes in the textural properties of the
spectral parametric maps, and tumor cell death measurements ob-
tained from histologic analysis. The analysis resulted in r2 values
ranging from 0.60 to 0.94 (Table 1) for single parameters. Multiple
regression analysis was also performed to find an optimal linear com-
bination of spectral and textural biomarkers to obtain a more robust
hybrid biomarker demonstrating higher levels of correlation with histo-
logic tumor cell death measurements. All parameters were first stan-
dardized to obtain random variables with mean of 0 and SD of 1,
having a similar potential importance in the model. The parameters
Figure 2. Conventional frequency ultrasound B-mode images with ROI parametric overlays of the 0-MHz intercept biomarker for tumors
treated with paclitaxel-doxorubicin and imaged before and after (A) 4, (B) 12, (C) 24, and (D) 48 hours. The top row of images consists of
data acquired before treatment, and the bottom row corresponds to those obtained at the specified times after the treatment. Scale bars
represent ∼5 mm. The color bar represents a scale encompassing ∼100 dBr.
Figure 3. Changes in ultrasound-based spectral biomarkers of treatment response compared to pretreatment. (A) MBFΔ results for
conventional and high-frequency data acquired before and at different times after treatment. Control animals are untreated; (B) 0-MHz
interceptΔ results for high- and low-frequency data acquired at different times after treatment. Dark and light bars represent conventional
low- and high-frequency data, respectively. Error bars represent ±1 SE. Stars represent statistically significant differences (P < .05) in
comparison to the control.
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Figure 4. (A–F) Relative changes in ultrasound-based textural biomarkers of treatment response for conventional and high-frequency
data acquired before and at different times after treatment. All the relative changes are in percent compared to pretreatment. Control
animals are untreated. Dark and light bars represent conventional low- and high-frequency data, respectively. Error bars represent ±1
SE. Stars represent statistically significant differences (P < .05) in comparison to the control.
Table 1. Summary of P Values Obtained from Statistical Tests of Significance Carried Out for the Histologic Tumor Cell Death Measurements, as well as for Changes in High-Frequency Ultrasound
(HFU)– and Conventional Frequency Ultrasound (CFU)–Based Biomarkers Using ANOVA Test over All Treatment Groups, Followed by LSD Post Hoc Test for Each Treated Group versus the
Untreated Control Group.
Cell Death
ANOVA Test
LSD Post Hoc Test (versus Untreated Control Group) Correlation with %Cell Death (r2)
4 Hours 12 Hours 24 Hours 48 Hours
0.005** 0.383 0.295 0.001** 0.027*
CFU HFU CFU HFU CFU HFU CFU HFU CFU HFU
MBF 0.000*** 0.042* 0.097 0.078 0.017* 0.018* 0.000*** 0.015* 0.000*** 0.005** 0.67
MBF contrast 0.016* 0.029* 0.107 0.172 0.024* 0.022* 0.001** 0.004** 0.015* 0.029* 0.63
MBF energy 0.003** 0.000*** 0.189 0.703 0.076 0.017* 0.000*** 0.000*** 0.028* 0.006** 0.93
MBF homogeneity 0.004** 0.034* 0.464 0.633 0.182 0.109 0.001** 0.008** 0.009** 0.117 0.92
0-MHz intercept 0.000*** 0.003** 0.308 0.394 0.749 0.077 0.000*** 0.002** 0.000*** 0.003** 0.61
0-MHz intercept contrast 0.016* 0.045* 0.425 0.186 0.091 0.024* 0.004** 0.006** 0.012* 0.036* 0.60
0-MHz intercept energy 0.011* 0.001** 0.474 0.422 0.097 0.039* 0.004** 0.000*** 0.009** 0.010* 0.79
0-MHz intercept homogeneity 0.002** 0.037* 0.707 0.404 0.276 0.043 0.001** 0.009** 0.008** 0.031* 0.94
The last column represents the r2 values obtained from regression analysis performed to evaluate correlations between changes in the conventional frequency quantitative ultrasound-based biomarkers and
the histologic tumor cell death estimates.
*Statistically significant (P < .05).
**Statistically highly significant (P < .01).
***Statistically extremely significant (P < .001).
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with no significant contribution to the model (P > .05) were then
eliminated through an iterative backward method. This resulted in a
final model only depending on MBF %energyΔ and 0-MHz inter-
cept %homogeneityΔ parameters (Equation 1), correlating to histo-
logic tumor cell death measurements with an r2 value of 0.97, i.e.,
Hybrid biomarker = 0:46 × standardizedfMBF %energyΔg + 0:54 × standardizedf0-MHz intercept %homogeneityΔgðA:U:Þ ð1Þ
Figure 5 presents fitted lines to the scatter data in conjunction with
the 95% confidence intervals for MBFΔ, MBF %energyΔ, 0-MHz
interceptΔ, 0-MHz intercept %homogeneityΔ, and the hybrid bio-
marker, respectively. Regression analysis indicated a strong correla-
tion, particularly, between quantitative ultrasound-based textural
biomarkers and histologic tumor cell death responses to treatment.
Discussion and Conclusions
The results presented in this study confirm, for the first time, that
quantitative ultrasound techniques at clinically relevant conventional
frequencies, in conjunction with textural characterization methods,
can be used to monitor noninvasively cell death progress in vivo.
In comparison with untreated control animals, ultrasound-based spec-
tral biomarkers (MBF and 0-MHz intercept parameters), and textural
biomarkers (contrast, energy, and homogeneity parameters extracted
from MBF and 0-MHz intercept parametric maps), indicated changes
associated with histologic increases in cell death.We have demonstrated
the possibility of cell death detection using high-frequency ultrasound
Figure 5. Results of regression analysis performed to evaluate correlations between changes in the conventional frequency quantitative
ultrasound-based biomarkers and tumor cell death measurements obtained from histologic analysis. The analysis resulted in an r2 value
of 0.67 (MBFΔ), 0.93 (MBF %energyΔ), 0.61 (0-MHz interceptΔ), 0.94 (0-MHz intercept %homogeneityΔ), and 0.97 (hybrid biomarker)
from left to right and top to bottom, respectively.
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previously [12–14]. Here, we demonstrate these methods coupled with
textural analysis in a clinically relevant ultrasound frequency range.
Changes in mean spectral parameters, as well as in textural patterns
of spectral parametric maps corresponding at different times after che-
motherapy administration, were detectable. Particularly in samples
demonstrating macroscopic areas of cell death, increased backscattered
signal intensity in the low- and high-frequency ultrasound images was
observed. Backscattered signal intensity increased for samples of differ-
ent tumor groups assessed at different times after chemotherapy treat-
ment. This was concordant with increases in cell death apparent
histologically. Data indicated that ∼20% cell death in an ∼1-cm xeno-
graft tumor was detectable after 12 to 24 hours of chemotherapy admin-
istration with statistical significance, in well-controlled animal tumor
models. This indicated a reasonable sensitivity of the conventional fre-
quency quantitative ultrasound techniques to detect noninvasively early
cell death changes in tumors.
Linear regression analysis performed demonstrated strong correla-
tions between changes in determined ultrasound-based biomarkers
with tumor cell death measurements obtained from histologic analy-
sis. Although single spectral biomarkers demonstrated a favorable cor-
relation with the amount of histologic cell death (with maximum r2 =
0.67, P < .001), textural biomarkers exhibited an even stronger cor-
relation (with maximum r2 = 0.94, P < .001). This suggests strong
potential for using the higher order information extracted from ultra-
sonic spectral parametric maps, instead of using a simple averaging,
to better estimate levels of cell death, noninvasively.
The determined spectral and textural biomarkers indicated similar
changes in trend for high- and low-frequency ultrasound data. This is
in line with the results of previous studies where it has been demon-
strated that nuclear morphology influences scattering at high and
lower ultrasound frequencies [13,15]. Confirmatory changes in statis-
tical parameters of the signal envelope were also observed with cell
death, for both high and conventional frequency ultrasound data.
These measures have been applied before using high-frequency ultra-
sound for cells treated with chemotherapy [11].
Previous investigations of ultrasonic cell death detection in vitro
and in vivo support the results presented in this study. Previous studies
include those investigations where apoptosis was induced in cells and
normal tissues using a variety of modalities and analyzed using high-
frequency ultrasound [8–15]. Those studies also indicated an important
role of nuclear structure in the detection of cell death. In particular, it
was demonstrated that nuclear condensation caused by the induction of
apoptotic death can lead to increases in backscattered signal intensity.
This is consistent with observations in this study using high- and now
low-frequency ultrasound. In addition, comparative studies performed
previously on low- and high-frequency ultrasound data from in vitro
cell models indicated a correspondence consistent with that seen here
[39]. Here, we followed cell death progression with time and thus
monitored the extent of cell death ultrasonically.
Samples imaged in this study using conventional frequency ultra-
sound demonstrated that increases in cell death had consequent changes
in spectral, textural, and statistical parameters. All such increases fol-
lowed the trends of increases in cell death in tumors as obtained from
histologic analyses. The fact the low-frequency data were parallel in
trend by the high-frequency data was confirmatory. This is despite
the fact that different scattering modes were potentially expected from
these two frequency ranges. It is expected thatmore Faran-like scattering
[40] would be observed with high-frequency ultrasound since cellular
components are approximately proportional to these wavelengths. In
contrast, at low frequencies, Rayleigh scattering [41] is anticipated to
be predominant as the cellular components are considerably smaller
than the ultrasound wavelengths. The observation that both ultrasound
ranges are sensitive to cell death is not necessarily surprising given that
ultrasound interacts with cell ensembles in both cases and nuclear struc-
ture in those ensembles changes with cell death. There are also cellular
changes in viscosity and elasticity, as well as density associated with cell
death [13]. Increases observed in ultrasound backscattered signal inten-
sity can bemainly linked to the condensation of nuclear structure during
apoptosis and cell death (pyknosis and karyorrhexis). There is now
extensive experimental evidence suggesting a role for nuclear structure
in contributing to ultrasound backscattered signals [13]. This evidence
includes the following:
1. In highly cellular xenograft tumors, backscattered signals and
spectra are identical to backscattered signals and spectra of
centrifuged cell models that mimic the histologic packing of
xenograft tumors [42]. Such packed cell models have no extra-
cellular matrix and collagen present yet exhibit nearly identical
backscatter profiles.
2. Different cell types may be differentiated on the basis of their
ultrasound spectra, now recognized to be linked to nuclear
size [15].
3. Calculated scatterer sizes from ultrasound backscattered signal
do not work out to be the same as cell sizes but coincide with
smaller sizes near that of nuclei, which again suggests an impor-
tant role of the nucleus [42].
It might be argued that measurable changes in backscatter character-
istics from micron-sized particles are not expected at low frequencies,
mainly due to loss of scattering strength of small scattering structures.
However, in the low- to mid-frequency range (near 10 MHz), bulk
changes in tissue are mostly related to ensembles of cells and nuclei
smaller than the wavelength of the ultrasound being used. Such
ensembles influence acoustic properties and thus ultrasound backscatter
characteristics [43]. When imaging cell samples, even at these low fre-
quencies, a speckle pattern is still formed indicating that many sub-
resolution scatterers contribute to detected signals [39]. Similar
conclusions can be made considering backscattered signal intensity
from tumor samples.
The textural parameters in this study based on spatial maps of
quantitative ultrasound spectral parameters were more sensitive to
cell death than averaged spectral parameters. They were able to detect
changes in tissue microstructures with a higher correlation to histo-
logic cell death. This is likely due to the fact that the tumor re-
sponses, as observed in this study in xenografts, are heterogeneous
(Figure 1) and not homogeneous. Thus, an analysis that takes those
features into account is, in particular, advantageous. Here, we studied
responses of tumors to chemotherapy, but the same method can be
applied in the situations where heterogeneous responses occur. This
can happen in radiation treatments [14], or even with photodynamic
therapy [9,13], or new vascular disrupting treatments [44].
The technique introduced in this work complements other imag-
ing methods, e.g., magnetic resonance imaging or positron emission
tomography, proposed to detect tumor responses [5,45,46]. Unlike
these methods, the quantitative ultrasound method relies on inherent
contrast changes arising from changes in acoustical properties as
cancer cells die. In addition, the preclinical work here applied in
xenograft models appears to be adaptable to human data for response
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monitoring [43,47] and may complement clinical methods (above)
for therapy response monitoring.
In conclusion, this study suggests that quantitative conventional
frequency ultrasound in conjunction with the textural analysis tech-
niques may be used to monitor cell death in vivo. Data were obtained
in a timeline basis, for five different times after chemotherapy in pre-
clinical breast cancer xenografts. Analyses indicated favorable cor-
relations between changes in ultrasonic quantitative biomarkers of
treatment response and the histologic extent of cell death, particularly
when textural characteristics of spectral parametric maps were applied.
This work forms the basis for the application of clinically relevant
conventional frequency approaches in vivo in cancer patients for moni-
toring and personalization of their cancer therapies. This is a clinical
application of the proposed method where the process to be monitored
generates the contrast by itself.
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Figure W1. (A) Changes in spectral slope biomarker (Spectral SlopeΔ), and (B) relative changes in ultrasound-based statistical biomarker
of treatment response (Rayleigh %σΔ), for conventional and high-frequency data acquired before and at different times after treatment.
The relative changes are in percent compared to pretreatment. Control animals are untreated. Dark and light bars represent conventional
low- and high-frequency data, respectively. Error bars represent ±1 SE. Stars represent statistically significant differences (P < .05) in
comparison to the control.
